The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Finnish time. About Nanoform. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

Containment 52

Containment Medicine Development Bioavailability 52

The Pharma Data

DECEMBER 8, 2020

Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. Forward-Looking Statements.

Bioavailability 52

Bioavailability Containment Sales Medicine 52

The Pharma Data

MAY 14, 2021

The natural green tea contained by this formula, and the broccoli leaf extracts are also powerful ingredients. Frank Neal is a pen name used for marketing purposes and to protect the author’s identity. It’s less than what you’d pay for fancy exotic groceries that you don’t even like eating.

Packaging 52

Packaging Packaging Production Bioavailability 52

The Pharma Data

NOVEMBER 19, 2020

These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Development 40

Development Bioavailability Production Drugs 40

The Pharma Data

NOVEMBER 17, 2020

LYT-100 is a deuterated, oral small molecule designed to overcome the challenges associated with pirfenidone, an approved and marketed anti-inflammatory and anti-fibrotic drug. Photo: Business Wire). For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh. Forward Looking Statement.

Production 52

Production Trials Bioavailability Drugs 52

The Pharma Data

DECEMBER 3, 2020

Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. In transplant recipients, reactivation of CMV can lead to serious consequences including loss of the transplanted organ and, in extreme cases, can be fatal.

Drugs 52

Drugs Medicine Trials Development 52

The Pharma Data

JANUARY 27, 2021

Clinical Studies XPhyto’s drug formulation business is focused on neurological indications with strong market demand and the potential for improved patient outcomes. Psychedelics could provide a major improvement over currently available therapeutics for a global market with unmet medical need.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

Pharmaceutical Technology

JUNE 14, 2023

The number of high-potency drug approvals has increased over the last decade, driven by the increasing use of APIs (Active Pharmaceutical Ingredients) in the pipeline and among marketed drugs. Containment challenges and opportunities High containment facilities guard against exposure to extremely potent products and cross-contamination.

Containment 130

Containment Manufacturing Contract Manufacturing Bioavailability 130

The Pharma Data

MAY 16, 2021

Contains a unique “living chemistry” that was poorly understood until recently…. We’ll start with all-natural food #1 which contains powerful compounds that…. Because this food also contains a mineral that’s proven to help men over 45 burn fat, build muscle, and bound with energy…. Because the next ingredient contains….

Production 52

Production Containment Research Doctors 52

Pharmaceutical Technology

FEBRUARY 3, 2023

There are a number of reasons why OSD forms dominate the market, not least because they are simple to administer, and it is easy to differentiate one OSD product from another. This heightens the risk of cross contamination, requiring effective containment solutions, especially when handling highly potent powders.

Contamination 130

Contamination Manufacturing Containment Production 130

Pharmaceutical Technology

APRIL 12, 2023

Containment and controlled substance capabilities are defining and necessary features for these manufacturing facilities, but not all contract manufacturers have the specialist equipment and capabilities required for high potency small molecule API production. The sampling device is suitable for operation in a vacuum environment.

Manufacturing 130

Manufacturing Production Containment Contamination 130

Pharmaceutical Technology

MARCH 7, 2023

Due to rising healthcare spending, launch of novel treatments, and the rise of chronic diseases in an aging population, the global pharmaceutical packaging equipment market is rapidly expanding. Recent analysis valued the market [i] at USD 8.5 Safety issues must also be addressed, such as containment and potential ignition factors.

Production 130

Production Containment Bioavailability Manufacturing 130

Pharmaceutical Technology

MARCH 21, 2023

In 2022, the largest study of its kind in Latin America published clinical evidence [ii] on the effectiveness and safety of CBD oil-based cannabis formulations, containing reassuring data on the efficacy, safety, and cost-effectiveness of the products to treat chronic pain. Please check your email to download the Whitepaper.

Production 243

Production Bioavailability Pharmacy Clinical Trials 243